Ascletis Pharma's (HKG:1672) investigational new drug application for a phase I trial for ASC50 for the treatment of mild-to-moderate plaque psoriasis has been cleared by the US Food and Drug Administration (FDA), a Thursday Hong Kong bourse filing said.
The study will be conducted at multiple sites in the US, with dosing of patients with mild-to-moderate plaque psoriasis expected to start in the third quarter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.